{"title":"拉坦前列素诱导的副作用及其潜在机制","authors":"X. Zhai, J. Samples","doi":"10.3109/15569520009068349","DOIUrl":null,"url":null,"abstract":"Latanoprost (13,16dihydro15R17-phenyl18,1 9,20-trinor-PGF2, isopropyl ester) is a synthetic analogue of prostaglandin Fza developed by Pharmacia and Upjohn as a glaucoma treatment. Since its approval by the Food and Drug Administration (FDA) in August, 1996, multiple published reports have linked a variety of side effects to the use of the drug, some of which are not listed in the original package insert. This review summarizes current understanding of latanoprost-induced side effects and explores potential mechanisms involved in causing these effects based on the available data on this class of medication from basic science and clinical re search.","PeriodicalId":17547,"journal":{"name":"Journal of Toxicology-cutaneous and Ocular Toxicology","volume":"69 1","pages":"177 - 197"},"PeriodicalIF":0.0000,"publicationDate":"2000-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Latanoprost-Induced Side Effects and Potential Mechanisms\",\"authors\":\"X. Zhai, J. Samples\",\"doi\":\"10.3109/15569520009068349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Latanoprost (13,16dihydro15R17-phenyl18,1 9,20-trinor-PGF2, isopropyl ester) is a synthetic analogue of prostaglandin Fza developed by Pharmacia and Upjohn as a glaucoma treatment. Since its approval by the Food and Drug Administration (FDA) in August, 1996, multiple published reports have linked a variety of side effects to the use of the drug, some of which are not listed in the original package insert. This review summarizes current understanding of latanoprost-induced side effects and explores potential mechanisms involved in causing these effects based on the available data on this class of medication from basic science and clinical re search.\",\"PeriodicalId\":17547,\"journal\":{\"name\":\"Journal of Toxicology-cutaneous and Ocular Toxicology\",\"volume\":\"69 1\",\"pages\":\"177 - 197\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Toxicology-cutaneous and Ocular Toxicology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/15569520009068349\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Toxicology-cutaneous and Ocular Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/15569520009068349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Latanoprost-Induced Side Effects and Potential Mechanisms
Latanoprost (13,16dihydro15R17-phenyl18,1 9,20-trinor-PGF2, isopropyl ester) is a synthetic analogue of prostaglandin Fza developed by Pharmacia and Upjohn as a glaucoma treatment. Since its approval by the Food and Drug Administration (FDA) in August, 1996, multiple published reports have linked a variety of side effects to the use of the drug, some of which are not listed in the original package insert. This review summarizes current understanding of latanoprost-induced side effects and explores potential mechanisms involved in causing these effects based on the available data on this class of medication from basic science and clinical re search.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
